TECX
NASDAQ HealthcareTectonic Therapeutic, Inc. - Common Stock
Biotechnology
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
�� 市场数据
| 价格 | $27.43 |
|---|---|
| 成交量 | 189,231 |
| 市值 | 517.58M |
| RSI（14日） | 48.1 |
| 200日均线 | $22.77 |
| 50日均线 | $29.17 |
| 52周最高 | $36.03 |
| 52周最低 | $14.39 |
| Forward P/E | -5.86 |
| Price / Book | 2.24 |
🎯 投资策略评分
TECX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (37/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (10/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TECX in your text
粘贴任何文章、记录或帖子 — 工具将提取 TECX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.